ALPL and hypophosphatasia: In a murine model for infantile HPP, TNAP knockout (Akp2−/− or Alpl−/−) mice, treatment with daily subcutaneous injections of asfotase alfa preserved life span, improved skeletal phenotypes, and prevented epileptic seizures and dental defects.(19, 20, 21) In humans, subcutaneous injections of asfotase alfa, three to seven times a week, in children or adults with HPP has demonstrated substantial and sustained efficacy with a good safety profile.